Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Foghorn Therapeutics, a biotech whose technology can affect one of the ways a cell regulates gene expression, has shown its approach has the potential to address a particular mutation tied to more ...

As Foghorn Therapeutics battles to free a trial from an FDA clinical hold, the biotech is now facing a partial hold for another program—meaning the company's two clinical assets are now tied up in red ...

Foghorn Therapeutics has been sitting in dock for over a year due to an FDA clinical hold placed on its blood cancer drug in the wake of a patient death. Now, the biotech can set sail once again. A ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--FogHorn, a leading developer of edge computing AI software for industrial and commercial Internet of Things (IoT) solutions, today announced plans to collaborate ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--FogHorn, a leading developer of Edge AI software for industrial and commercial Internet of Things (IoT) solutions, today announced its ranking as the Overall Leader ...

FogHorn, a Silicon Valley-based startup, is one of the early movers in the IIoT and edge computing market. The company has raised a total of $47.5M in funding over four rounds. The latest funding came ...

New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in ...